Glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, are highly effective at helping people lose weight and ...

Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and type 2 diabetes, a new analysis suggests. Data from a trial funded by Novo ...

In prespecified analyses from the SELECT trial, semaglutide reduced major adverse cardiovascular events (MACE) compared with placebo, with only about one-third of benefit mediated by waist ...

A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight ...

Add Yahoo as a preferred source to see more of our stories on Google. On 10 November at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, data from the SCORE-HF ...

Database study compares protective effect of new GLP-1-based drugs in cardiovascular risk patients Evident heart benefits beyond weight loss Only few differences in effectiveness between semaglutide ...

Weight loss jabs may help prevent heart attacks and strokes - regardless of how much fat people lose while taking the drug. Being overweight can drastically increase the risk of heart related problems ...

A large VHA real-world analysis compared GLP‑1 receptor agonists (~132,000) with sulfonylureas (>201,000), focusing on major adverse cardiovascular outcomes in type 2 diabetes. Continuous GLP‑1 ...

HCM causes the heart muscle to abnormally thicken, making it harder for the heart to pump blood effectively. According to the ...

Recent studies show semaglutide (Ozempic) can slow kidney-function decline and lower cardiovascular risks in type 2 diabetes patients, but AI analysis of user reports suggests lesser-known side ...

Post hoc SOUL analyses showed rapid reductions at 13 weeks across glycemia, adiposity, hemodynamics, inflammation, and select lipids versus placebo on top of contemporary standard of care. Durability ...